NCT01938352View on ClinicalTrials.gov

Evaluation of the Protective Efficacy and Safety of CR8020 in an Influenza Challenge

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

October 2, 2013

Primary Completion Date

January 22, 2014

Study Completion Date

January 22, 2014

Conditions
Influenza
Interventions
BIOLOGICAL

CR8020

CR8020 15 mg/kg, administered by intravenous infusion

BIOLOGICAL

Placebo

Placebo (hydrous dextrose in water for injection), administered by intravenous infusion

Trial Locations (1)

Unknown

London

All Listed Sponsors
collaborator

Retroscreen Virology Ltd.

INDUSTRY

lead

Crucell Holland BV

INDUSTRY

NCT01938352 - Evaluation of the Protective Efficacy and Safety of CR8020 in an Influenza Challenge | Biotech Hunter | Biotech Hunter